As the landscape of available antiplatelet agents expands and becomes more widely examined, optimal administration of pre- and post-procedural antiplatelet therapy is of paramount importance to patient outcomes. Chief among these agents, the use of aspirin has long represented a source of clinical debate in cardiovascular medicine. This program examines the evidence for use of aspirin by the inverventionalist, with evidence-based discussion of clinical risks and benefits of aspirin use in various clinical contexts. Topics discussed will include integration of aspirin in ACS after PCI, chronic aspirin use in cardiovascular patients, and reduction of aspirin use in ACS and PCI.
CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. Documentation of awarded credit is provided for participants in exchange for completed activity evaluations. Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Joe Heard at jheard@crf.org .
By the end of this program, participants should be able to:
• Describe the fundamental mechanisms of action of aspirin and bioavailability of various aspirin formulations
• Assess the determinants and clinical significance of interactions between aspirin and P2Y12 inhibitors
• Identify approaches to effectively integrating and/or reducing use of aspirin in various clinical contexts
This educational activity is designed for interventional cardiologists, clinical cardiologists, and other healthcare professionals involved in the management of patients with cardiovascular disease.
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the course directors of this activity.
All Planners (Directors, Co-Directors and Chairs) and Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Anyone in noncompliance with this policy is not permitted to participate in this activity.
KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E/S/O) Equity/Stock(s)/Options (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit
Program Chair: Dominick J. Angiolillo: (G/R) (Institutional payments) Amgen; AstraZeneca; Bayer; Biosensors; CeloNova; CSL Behring; Daiichi-Sankyo; Eisai; Eli-Lilly; Gilead; Idorsia; Janssen; Matsutani Chemical Industry Co.; Merck; Novartis; Osprey Medical; Renal Guard Solutions; Spartan; Scott R. MacKenzie Foundation (C/H/S) (individual payments) Amgen; Aralez; AstraZeneca; Bayer; Biosensors; Boehringer Ingelheim; Bristol-Myers Squibb, Chiesi; Daiichi-Sankyo, Eli Lilly; Haemonetics; Janssen; Merck, PhaseBio; PLx Pharma; Pfizer; Sanofi; The Medicines Company; CeloNova
Davide Capodanno: (C/H/S) Bayer; Sanofi Aventis; Daiichi Sankyo; Boehringer Ingelheim; AstraZeneca; Pfizer
C. Michael Gibson: (G/R) Angel Medical Corporation; Janssen; Bristol-Myers Squibb; CSL Behring; Portola Pharmaceuticals; SCAD Alliance; Baim Institute (E/S/O) nference, Inc. (C/H/S) Angel Medical Corporation; Boston Clinical Research Institute; Caladrius Biosciences; Cardiovascular Research Foundation; CeleCor Therapeutics; Eli Lilly; GE Healthcare; Medtelligence; Novo Nordisk; PharmaMar; Portola; Thrombolytic Science; Bayer; Janssen/ J&J; WedMD ; Spouse (employee of Boston Clinical Research Institute, she has equity postion (E/S/O) Amarin; Amgen; Bayer/Janssen/J&J; Boehringer Ingelheim; Boston Scientific Corporation; Cardiovascular Research Foundation; Calardius Biosciences; CeleCor Therapeutics; Chiesi, DCRI; Eli Lilly; GE Healthcare; Gilead Sciences, Inc.; Impact Bio, LTD; The Medicines Company; (C/H/S) (money paid to hospital) Bayer Corporation; Janssen Pharmaceuticals; Medtelligence; MedImmune; The Medicines Company; Microport; Merck & Co. Inc.; Novo Nordisk, PERT Consortium; CSL Behring; PharmaMar; Portola; Thrombolytic Science; Sanofi; Somahlution: Verseon Corporation
Sanjit S. Jolly: (G/R) Medtronic; Boston Scientific Corporation; Bayer (Institutional Grant support)
Program Chair: Gregg W. Stone: (G/R) Shockwave; Valfix; Reva; TherOx; Vascular Dynamics; Robocath; HeartFlow; W.L. Gore & Associates; Ablative Solutions; Miracor; Neovasc; V-wave; Abiomed; MAIA Pharmaceuticals; (C/H/S) Qool Therapeutics; Cagent; Applied Therapeutics; Biostar family of funds; MedFocus family of funds (G/R) (C/H/S) Ancora; SpectraWave; Orchestra Biomed
Freek Verheugt: (C/H/S) Bayer AG; AstraZenca; Boston Scientific Corporation; Bristol-Myers Squibb; Daiichi-Sankyo/Elil Lilly and Company
Content Reviewer(s)
Gary S. Mintz, MD – Nothing to disclose
Joe Heard, MHA – Nothing to disclose
Colleen Whelan – Nothing to disclose
This program is sponsored by the Cardiovascular Research Foundation and supported through an unrestricted grant from PLx Pharma. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.